Meeting
2012 ASCO Annual Meeting
Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.
Presenter
Jeffrey Howard Lipton, MD, PhD
Princess Margaret Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00760877
Citation
J Clin Oncol 30, 2012 (suppl; abstr 6505^)
Abstract #
6505^
Abstract Disclosures
Similar Videos & Slides
Speaker: Karen Elizabeth Hoffman, MD, MHSc, MPH
Videos & Slides
2011 ASCO Annual Meeting
The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up.
Speaker: Giuseppe Saglio, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
Time to Reflect on What We Do Below the Peritoneal Reflection
Speaker: Christopher Leigh Hallemeier, MD
Speaker: William Regine, MD